Corporate Overview

At Janux, we are developing unique immunotherapies that have the potential to generate tumor-specific immune responses to attack and kill tumors without destroying a patient’s healthy tissue. We believe that combining Janux’s tumor-specific activation with multi-stage anti-tumor signaling will significantly improve safety, expand the therapeutic dosing window, and maximize patient response.

Latest News

View all news

Latest Presentation

Latest Events

View All Events

Q3

2023

Latest Quarterly Reports